Fiche société
Kyverna Therapeutics
Traitements, essais et publications liés.
Traitements5programmes
Essais3liés
Publications0liées
SourceDBlocale
Traitements
5| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| KYV-101 anti-CD19 CAR-T cell therapyA Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis | Lupus | Phase 1/2 | Thérapie cellulaire | Germany | À vérifier |
| Standard lymphodepletion regimenA Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis | Lupus, Myasthénie | Phase 1/2 | Thérapie cellulaire + Immunomodulation | Germany | À vérifier |
| Standard lymphodepletion regimenA Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis | Myasthénie | Phase 2/3 | Thérapie cellulaire + Immunomodulation | United States, Australia, Brazil, Germany, Saudi Arabia, United Kingdom | À vérifier |
| KYV-101 anti-CD19 CAR-T cell therapyA Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis | Lupus | Phase 1/2 | Thérapie cellulaire | United States | À vérifier |
| KYV-101 anti-CD19 CAR-T cell therapyA Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis | Lupus | Phase 1/2 | Thérapie cellulaire | Germany | À vérifier |
Essais cliniques
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| KYV-101 anti-CD19 CAR-T cell therapy | Lupus | Phase 1/2 | NCT06342960 | KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis | TERMINATED |
| KYV-101 anti-CD19 CAR-T cell therapy | Lupus | Phase 1/2 | NCT05938725 | KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis | TERMINATED |
| Standard lymphodepletion regimen | Myasthénie | Phase 2/3 | NCT06193889 | KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis | RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||